JLE

Néphrologie & Thérapeutique

MENU

Du transfert à la transition : mise au point et proposition de la Commission de dialyse de la SFNDT Volume 19, issue 3, June 2023

Figures


  • Figure 1

  • Figure 2
Authors
au nom de la Commission de dialyse de la SFNDT
1 Centre universitaire des maladies rénales, CHU de Caen, Avenue de la côte de Nacre, 14033 Caen Cedex 9, France
2 U1086 Inserm-Anticipe, Centre régionalde lutte contre le cancer François Baclesse, 3, avenue du général Harris, 14076 Caen Cedex 5, France
3 Normandie Université, Unicaen, UFR de médecine, 2, rue des Rochambelles, 14032 Caen Cedex, France
4 Hôpital Erasme, ULB, département de néphrologie, dialyse et transplantation, Route de Lennik 808, 1070 Bruxelles, Belgique
5 Hôpital universitaire Hassan II, service néphrologie, dialyse et transplantation, Fez, Maroc
6 Laboratoire d’épidémiologie et de recherche en sciences de la santé (ERESS), Faculté de médecine, Université Sidi Mohammed Ben Abdellah, Fez, Maroc
Correspondance : A. Boyer
annabel.boyer@wanadoo.fr

Over the course of their disease, patients with chronic kidney disease (CKD) will be treated by several kidney replacement therapy (KRT) modalities. The transitions between KRT modalities can be experienced as traumatic by patients, and are associated with an increased morbidity and mortality, notably when they are not anticipated. Planning these transition phases could reduce the psychological trauma induced by the transfer, as well as reduce the risk of morbidity and mortality. However, the lack of a clear definition of a transfer, and the lack of criteria enabling the identification of patients at risk of transfer, prevents the anticipation of these transition phases at high risk for patients. We here discuss the various possible causes and risk factors of transfer from peritoneal dialysis (PD) to hemodialysis as well as transfer from hemodialysis to PD. The dialysis Commission of the Société francophone de néphrologie, dialyse et transplantation (SFNDT) makes some proposals to improve transition phases, such as the identification of patients at risk, specific PD programs for unplanned PD start, transition unit and hybrid therapy.